ACUTE CORONARY syndromes (ACS) represent the most common cause of death in the western world.
1,2 Considerable variability exists in the risk for adverse events across the spectrum of ACS. Different presenting characteristics, in large part related to identification of varying levels of risk, have become important factors in deciding on the level of care and choice of interventional and medical therapies.
3-5 Current guidelines from the American College of Cardiology/American Heart Association
3,4 and the European Society of Cardiology
6 recommend that certain pharmacological and interventional strategies are most appropriate for higher-risk groups. Despite these recommendations, some contemporary registry data suggest that more aggressive therapy is not necessarily targeted at higher-risk patients, even in more cost-constrained health care systems.
7 Although individual demographic and clinical characteristics may be associated with an increased risk for adverse outcomes, one must take multiple factors into account simultaneously to optimize the ability to assess risk accurately.